TPEX:3205

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Sagittarius Life Science

Market Cap

NT$929.2m

Last Updated

2021/06/10 16:47 UTC

Data Sources

Company Financials

Executive Summary

Sagittarius Life Science Corporation operates as a biotechnology research company. More Details


Snowflake Analysis

Flawless balance sheet and overvalued.

Share Price & News

How has Sagittarius Life Science's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 3205 is less volatile than 75% of TW stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: 3205's weekly volatility (5%) has been stable over the past year.


Market Performance


7 Day Return

0%

3205

-0.001%

TW Personal Products

-1.4%

TW Market


1 Year Return

-28.6%

3205

-2.7%

TW Personal Products

45.5%

TW Market

Return vs Industry: 3205 underperformed the TW Personal Products industry which returned -4.5% over the past year.

Return vs Market: 3205 underperformed the TW Market which returned 44.3% over the past year.


Shareholder returns

3205IndustryMarket
7 Day0%-0.001%-1.4%
30 Day3.6%-0.7%2.1%
90 Day-10.5%-4.9%4.5%
1 Year-28.6%-28.6%0.8%-2.7%50.4%45.5%
3 Year-56.1%-57.3%-6.3%-13.7%69.8%50.3%
5 Year-84.0%-85.6%24.3%8.3%138.1%95.7%

Long-Term Price Volatility Vs. Market

How volatile is Sagittarius Life Science's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Sagittarius Life Science undervalued compared to its fair value and its price relative to the market?

1.65x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 3205's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 3205's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 3205 is unprofitable, so we can't compare its PE Ratio to the TW Personal Products industry average.

PE vs Market: 3205 is unprofitable, so we can't compare its PE Ratio to the TW market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 3205's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 3205 is good value based on its PB Ratio (1.7x) compared to the TW Personal Products industry average (2.2x).


Future Growth

How is Sagittarius Life Science forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

18.7%

Forecasted Household industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Sagittarius Life Science has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Sagittarius Life Science performed over the past 5 years?

-64.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 3205 is currently unprofitable.

Growing Profit Margin: 3205 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 3205 is unprofitable, and losses have increased over the past 5 years at a rate of 64.2% per year.

Accelerating Growth: Unable to compare 3205's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 3205 is unprofitable, making it difficult to compare its past year earnings growth to the Personal Products industry (4.7%).


Return on Equity

High ROE: 3205 has a negative Return on Equity (-15.05%), as it is currently unprofitable.


Financial Health

How is Sagittarius Life Science's financial position?


Financial Position Analysis

Short Term Liabilities: 3205's short term assets (NT$482.8M) exceed its short term liabilities (NT$110.7M).

Long Term Liabilities: 3205's short term assets (NT$482.8M) exceed its long term liabilities (NT$23.9M).


Debt to Equity History and Analysis

Debt Level: 3205 is debt free.

Reducing Debt: 3205 has no debt compared to 5 years ago when its debt to equity ratio was 3.7%.

Debt Coverage: 3205 has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: 3205 has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Sagittarius Life Science current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 3205's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 3205's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 3205's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 3205's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: 3205 is not paying a notable dividend for the TW market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 3205's dividend in 3 years as they are not forecast to pay a notable one for the TW market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Sagittarius Life Science has no CEO, or we have no data on them.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Sagittarius Life Science Corp's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Sagittarius Life Science Corp
  • Ticker: 3205
  • Exchange: TPEX
  • Founded: 1987
  • Industry: Personal Products
  • Sector: Household
  • Market Cap: NT$929.177m
  • Shares outstanding: 32.55m
  • Website: https://www.naturalbiokey.com

Number of Employees


Location

  • Sagittarius Life Science Corp
  • No.3, Yuanqu Street
  • 10F-6
  • Taipei
  • 115
  • Taiwan

Listings


Biography

Sagittarius Life Science Corporation operates as a biotechnology research company. It engages in the development of Chinese herbal medicine technology platform for the treatment of various diseases. The co...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/06/10 16:47
End of Day Share Price2021/06/10 00:00
Earnings2021/03/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.